One additional Exempt Distribution:

2023-11-10 (Alberta)

Promissory Note: $228,013.50 (CAN)

With 300,000 warrants @ $1.04, Expire 2028-11-10.

____________________________________________________________________________

I questioned Chris (IR) if management is considering a Zenith IPO with the help of Cencora, with so many Clinical Trials ongoing with ZEN-3694, in collaboration with BP, to help fund Resverlogix BOM2. And that could be the quickest way to get the necessary funding for it, as opposed to selling to a third-party royalty on ZEN-3694. I also questioned the lack of operational funding for RVX and that the cupboard is bare!

His responses have become a bit cliche!

"Thank you for your questions. I want to assure you that the management teams of Resverlogix and Zenith Epigenetics are doing everything they can to secure the financing and partnerships necessary to propel both companies forward. Our ultimate objective is to advance the development of apabetalone and ZEN-3694 so that we can get them into the hands of patients who need them and deliver value for our shareholders. Our teams are actively pursuing multiple paths forward to reach this goal, among them the royalty sale that was mentioned at the AGM. I do not have any additional details about our strategic plans, beyond what has already been shared publicly, that I can disclose to you at this time.

Thank you for your patience and understanding."

I remain hopeful they'll get it done, one way or another, and soon.

Koo